Total Funding
56
35
Total FundingPost-IPO Debt raised
Growth Score
-6 pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
208661
MagForce NT GmbH, a medical device company, operates in the field of nanotechnology-based cancer treatment in Germany
Ben J. Lipps: CEO- Eva Steier: Safety Officer & Risk Manager
About the Company
MagForce is forging new paths to treat cancer successfully and gently. With NanoTherm® Therapy System (NTTS), we have developed an innovative approach based on nanotechnology, which we want to make available to patients worldwide. And we are getting closer and closer to this goal. NTTS is the first and only nanotechnology-based therapy with
European approval for treating recurrent Glioblastoma, a deadly brain tumor. To date, many patients diagnosed with Glioblastoma tumors have improved their quality of life after using our technology.
